AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Phase II trial of GVAX cancer vaccine initiated.(Brief Article)
2002 JUL 3 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (CEGE) announced the initiation of a phase II clinical trial of GVAX pancreatic cancer vaccine in patients with inoperable or metastatic pancreatic cancer. This trial was prompted by compelling results from an initial phase I clinical trial of GVAX pancreatic cancer vaccine which demonstrated prolonged, disease-free survival in three of eight patients treated at the higher dose levels.
The new phase II trial is in addition to a second ongoing phase II trial in patients with operable pancreatic cancer who receive GVAX pancreatic cancer vaccine in combination with pancreatic cancer surgery and standard adjuvant radiation and chemotherapy. The new trial is expected to enroll approximately 40 patients and will be conducted at medical centers across the United States.
The initial phase I trial of GVAX pancreatic cancer vaccine was conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in 14 patients who received the vaccine following surgical resection of their tumor together with standard adjuvant radiation and chemotherapy. The results of this trial which were first reported in the Journal of Clinical Oncology in January 2001, revealed that three of eight patients who received the higher doses of vaccine were alive and disease-free at 38, 35, and 33 months after diagnosis, and this continues to be true at their most recent follow-up. In addition, the three patients with prolonged disease-free survival had biopsy-proven vaccine-induced antitumor immunity, a finding which was absent in the other five patients in the same treatment groups who had progressive pancreatic cancer. The significance of these findings was underscored by the fact that all three long term survivors were judged to be at high risk for recurrent cancer due to microscopic evidence of pancreatic tumor following surgery or metastatic tumor in pancreatic lymph nodes. As with other GVAX clinical trials, vaccine ...
- Data from Phase I Trial of Oncophage Cancer Vaccine in Pancreatic Cancer...
- Press release article from: Business Wire September 22, 2003 700+ words
...Years Reported in Pancreatic Cancer Patients Receiving...s personalized cancer vaccine Oncophage(R...with nonmetastatic pancreatic cancer, which were highlighted...of patients with pancreatic cancer die within two years...
- Initial clinical data from GVAX pancreatic cancer vaccine program.
- Newspaper article from: Vaccine Weekly July 28, 2004 700+ words
...clinical trial of GVAX pancreatic cancer vaccine in patients with inoperable...of the company's GVAX pancreatic cancer vaccine program. These 2 trials...up to 6 doses of GVAX pancreatic cancer vaccine at 21-day intervals...
- Cell Genesys Reports Initial Clinical Data From GVAX(R) Pancreatic Cancer...
- Press release article from: PR Newswire June 26, 2004 700+ words
...clinical trial of GVAX(R) pancreatic cancer vaccine in patients with inoperable...company's GVAX(R) pancreatic cancer vaccine program. These two trials...six doses of GVAX(R) pancreatic cancer vaccine at 21-day intervals...
- Cell Genesys Reports Publication of Additional Results From Phase 1 Clinical...
- Press release article from: PR Newswire August 19, 2004 700+ words
...immunologic data for GVAX(R) pancreatic cancer vaccine, a non patient-specific...molecule found on GVAX(R) pancreatic cancer vaccine cells, and that the specificity...1 trial of GVAX(R) pancreatic cancer vaccine was conducted at the Johns...
- Cell Genesys Announces Initiation of Phase II Clinical Trial of GVAX(R)...
- Press release article from: PR Newswire October 22, 2001 700+ words
...clinical trial of GVAX(R) pancreatic cancer vaccine which demonstrated antitumor...I trial of GVAX(R) pancreatic cancer vaccine was conducted in 14 patients...obtained with GVAX(R) pancreatic cancer vaccine particularly with respect...
- Cell Genesys Updates Results From Initial Clinical Trial Of GVAX(R) Pancreatic...
- Press release article from: PR Newswire January 2, 2001 700+ words
...initial trial of GVAX(R) pancreatic cancer vaccine conducted by Johns Hopkins...clinical trial of GVAX(R) pancreatic cancer vaccine in approximately 60 patients...I trial of GVAX(R) pancreatic cancer vaccine was conducted in 14 patients...
- Pancreatic cancer. (In the Pipeline).(Cell Genesys begins Phase II trial of...
- Newspaper article from: Drug Utilization Review December 1, 2001 700+ words
...of GVAX vaccine in patients with pancreatic cancer who have undergone surgical resection...the safety and efficacy of GVAX cancer vaccine used in combination with surgical resection of pancreatic cancer followed by standard adjuvant radiation...
- Early Results Using Therapeutic Pancreatic Cancer Vaccine Show Promise.
- News wire article from: Ascribe Higher Education News Service November 15, 2005 700+ words
...results of a treatment vaccine for pancreatic cancer, a disease with few options and...improvement over most published results of pancreatic cancer treatment studies," says Daniel...recently, most studies have shown pancreatic cancer survival rates at about 63 percent...
Source: HighBeam Research, Phase II trial of GVAX cancer vaccine initiated.(Brief Article)